Preclinical evaluation of antigen-specific nanotherapy based on phosphatidylserine-liposomes for type 1 diabetes
Villalba Felipe, Adrián (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Rodríguez-Fernández, Silvia (Institut Germans Trias i Pujol)
Ampudia Carrasco, Rosa María (Institut Germans Trias i Pujol)
Cano-Sarabia, Mary (Institut Català de Nanociència i Nanotecnologia)
Perna-Barrull, David (Institut Germans Trias i Pujol)
Bertran-Cobo, Cesc (Institut Germans Trias i Pujol)
Ehrenberg, Clara (Institut Germans Trias i Pujol)
Maspoch Comamala, Daniel (Institut Català de Nanociència i Nanotecnologia)
Vives Pi, Marta (Institut Germans Trias i Pujol)
Universitat Autònoma de Barcelona

Date:	2020
Abstract:	Type 1 diabetes (T1D) is an autoimmune disease caused by the destruction of insulin-producing cells. Due to the ability of apoptotic cells clearance to induce tolerance, we previously generated liposomes rich in phophatidylserine (PS) -a feature of apoptotic cells- loaded with insulin peptides to mimic apoptotic beta-cells. PS-liposomes arrested autoimmunity in experimental T1D through the induction of tolerance. The aim of this study was to investigate the potential of several peptides from different T1D autoantigens encapsulated in (PS)-liposomes for T1D prevention and to assess its safety. T1D autoantigens (Insulin, C-peptide, GAD65 and IA2) were encapsulated in PS-liposomes. Liposomes were administered to the 'gold-standard' model for the study of autoimmune T1D, the Non-Obese Diabetic mouse, that spontaneously develop the disease. Safety and toxicity of liposomes were also determined. Only PS-liposomes encapsulating insulin peptides decrease T1D incidence in the Non-Obese Diabetic mouse model. Disease prevention correlates with a decrease in the severity of the autoimmune islet destruction driven by leukocytes. PS-liposomes neither showed toxic effect nor secondary complications. Among the here referred autoantigens, insulin peptides are the best candidates to be encapsulated in liposomes, like an artificial apoptotic cell, for the arrest of autoimmunity in T1D in a safe manner.
Grants:	European Commission 618337 European Commission 290846 Ministerio de Economía y Competitividad FIS2012-37549-C05-02 Ministerio de Economía y Competitividad FIS2011-23713 Ministerio de Economía y Competitividad CSD2007-00050
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Nanovesicles ; Autoimmunity ; Immunotherapy
Published in:	Artificial Cells, Nanomedicine and Biotechnology, Vol. 48, issue 1 (2020) , p. 77-83, ISSN 2169-141X

DOI: 10.1080/21691401.2019.1699812

8 p, 1.3 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Experimental sciences > Catalan Institute of Nanoscience and Nanotechnology (ICN2)
Articles > Research articles
Articles > Published articles